{"id":"NCT02369653","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase","officialTitle":"A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-22","primaryCompletion":"2021-07-07","completion":"2021-07-07","firstPosted":"2015-02-24","resultsPosted":"2022-03-08","lastUpdate":"2022-03-08"},"enrollment":512,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Lymphoma","Acute Lymphoblastic Leukemia"],"interventions":[{"type":"DRUG","name":"Apixaban","otherNames":[]},{"type":"OTHER","name":"No systemic anticoagulant prophylaxis","otherNames":[]}],"arms":[{"label":"Apixaban","type":"EXPERIMENTAL"},{"label":"No systemic anticoagulant prophylaxis","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)","primaryOutcome":{"measure":"The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death","timeFrame":"From first dose up to approximately 40 days after first dose","effectByArm":[{"arm":"Apixaban","deltaMin":31,"sd":null},{"arm":"Standard of Care","deltaMin":45,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0403"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":96,"countries":["United States","Australia","Belgium","Canada","Czechia","Hungary","Mexico","New Zealand","Poland","Puerto Rico","Russia","South Korea"]},"refs":{"pmids":["40505060","37980924"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":250},"commonTop":["Anaemia","Platelet count decreased","Constipation","Alanine aminotransferase increased","Abdominal pain"]}}